Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 December, 2018 04:32 IST
Zydus Cadila gets Mexican regulatory authority's nod for Lipaglyn
Source: IRIS | 13 Nov, 2017, 11.41AM
Comments  |  Post Comment

Zydus announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
 
Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).
 
''Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia,'' said Pankaj Patel, Chairman, Zydus Group, and added, ''This approval of Saroglitazar in Mexico is a major milestone for the company.''

Shares of the company declined Rs 27.65, or 5.78%, to trade at Rs 451.00. The total volume of shares traded was 51,256 at the BSE (11.17 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Suzlon secures 50.4 MW order from Atria Power - 13-Dec-2018 13:11
Vikas Wsp wins orders worth Rs 2.06 bn - 13-Dec-2018 12:18
Strides Pharma receives USFDA approval for Lidocaine ointment - 13-Dec-2018 10:00
Tata Power eevamps customer portal - 13-Dec-2018 09:31
NBCC wins order worth Rs 1.72 bn from Govt of India - 13-Dec-2018 09:26
Ashok Leyland signs defence agreement with ELBIT Systems - 12-Dec-2018 09:41
Wipro launches automotive innovation center in Michigan - 12-Dec-2018 09:37
Liva Pharma gets USFDA approval for Ranitidine injection - 12-Dec-2018 09:35
Dr Reddy's Labs launches Omeprazole tablets in US market - 12-Dec-2018 09:31
Strides Vivimed JV receives consent for Albendazole tablets - 12-Dec-2018 09:27
Unichem Lab gets tentative nod for Tadalafil tablets - 12-Dec-2018 09:25
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer